Published in final edited form as:

Acta Neuropathol. 2014 March ; 127(3): 441–450. doi:10.1007/s00401-013-1211-9.

Staging TDP-43 pathology in Alzheimer's disease

Keith A. Josephs, MD, MST, MSc¹, Melissa E. Murray, PhD⁴, Jennifer L. Whitwell, PhD², Joseph E. Parisi, MD³, Leonard Petrucelli, PhD⁴, Clifford R. Jack Jr., PhD², Ronald C. Petersen, PhD, MD¹, and Dennis W. Dickson, MD⁴

¹Department of Neurology, Behavioral Neurology, Mayo Clinic Rochester MN

²Department of Radiology, Mayo Clinic Rochester MN

³Department of Laboratory Medicine & Pathology, Neuropathology, Mayo Clinic Rochester MN

⁴Department of Neuroscience, Mayo Clinic, Jacksonville, FL

Abstract

TDP-43 immunoreactivity occurs in 19–57% of Alzheimer's disease (AD) cases. Two patterns of TDP-43 deposition in AD have been described involving hippocampus (Limbic) or hippocampus and neocortex (Diffuse), although focal amygdala involvement has been observed. In 195 AD cases with TDP-43, we investigated regional TDP-43 immunoreactivity with the aim of developing a TDP-43 in AD staging scheme. TDP-43 immunoreactivity was assessed in amygdala, entorhinal cortex, subiculum, hippocampal dentate gyrus, occipitotemporal, inferior temporal and frontal cortices, and basal ganglia. Clinical, neuroimaging, genetic and pathological characteristics were assessed across stages. Five stages were identified: stage I showed scant-sparse TDP-43 in the amygdala only (17%); stage II showed moderate-frequent amygdala TDP-43 with spread into entorhinal and subiculum (25%); stage III showed further spread into dentate gyrus and occipitotemporal cortex (31%); stage IV showed further spread into inferior temporal cortex (20%); and stage V showed involvement of frontal cortex and basal ganglia (7%). Cognition and medial temporal volumes differed across all stages and progression across stages correlated with worsening cognition and medial temporal volume loss. Compared to 147 AD patients without TDP-43, only the Boston Naming Test showed abnormalities in stage I. The findings demonstrate that TDP-43 deposition in AD progresses in a stereotypic manner that can be divided into five distinct topographic stages which are supported by correlations with clinical and neuroimaging features. Given these findings, we recommend sequential regional TDP-43 screening in AD beginning with the amygdala.

Keywords

Alzheimer disease; TDP-43; amygdala; TDP-43 type; staging; MRI

Introduction

In 2006, two independent investigators reported that the TAR DNA binding protein of 43 kDa (TDP-43) was accumulated pathologically in the brains of patients with frontotemporal lobar degeneration (FTLD) and with motor neuron disease (MND) [2,31]. Subsequently, we

Corresponding Author Keith A. Josephs, MD, MST, MSc, Professor of Neurology, Mayo Clinic, Neurodegenerative Diseases, Rochester MN, 55905, Tele: (507)-538-1038, Fax: (507)-538-6012, josephs.keith@mayo.edu.

Conflict of Interest

The authors declare that they have no conflicts of interest

demonstrated that TDP-43 pathology is also detected in the brains of patients with Alzheimer's disease (AD) [1]. This finding has been confirmed by many different groups of investigators [3,4,9,14,15,18,20,22,33,37]. When studies that had assessed more than 50 AD patients were reviewed [1,3,4,9,37] (Table 1), the proportion of AD patients with TDP-43 ranged from 19–57% and a common finding across studies was that the presence of TDP-43 was associated with older age at death.

We have previously demonstrated that the distribution of TDP-43 in AD is variable and can show one of two patterns [1]. In the first pattern, TDP-43 immunoreactivity is limited to the entorhinal cortex and dentate gyrus of the hippocampus with minimal or no involvement of occipitotemporal cortex (OTC) while in the second pattern, immunoreactivity is more widespread and involves OTC and inferior temporal gyri. While we refer to the former as limbic, and the latter as diffuse, a subsequent study of an independent series of 29 AD cases found that TDP-43 can deposit in the amygdala without there being additional involvement of the dentate gyrus of the hippocampus or involvement elsewhere [15]. In fact, it is clear that studies which assess the amygdala find a higher proportion of AD patients with TDP-43 immunoreactivity (Table 1). Furthermore, the identification of focal amygdala involvement raises the question of whether there is a sequential progression of TDP-43 deposition in AD that starts in the amygdala.

Variability in morphology and distribution of neuronal inclusions in FTLT led to two independent methods to subtype FTLT by ubiquitin [25,34]. The two classification systems were harmonized [26], although the schemes did not provide a means for classifying TDP-43 that occurs in the setting of AD and other disorders, such as amyotrophic lateral sclerosis (ALS). Three main subtypes were recognized: Type A was characterized by pleomorphic neuronal cytoplasmic inclusions (NCIs), sometimes accompanied by neuronal intranuclear inclusions (NIIs), as well as dystrophic neurites (DNs) that were most numerous in the upper cortical layers; Type B had a predominance of NCIs, as well as cytoplasmic TDP-43 that does not form well-defined inclusions ("pre-inclusions") with minimal DNs; and Type C had a predominance of DNs, which were often longer and thicker than DNs in Type A and they were found in all cortical layers with minimal NCIs. In neither Type B nor Type C are NIIs common. Unfortunately, in these typing schemes, the characterization was limited to assessing hippocampus and neocortex.

The aim of this study was to develop a staging scheme of TDP-43 progression in AD and to determine whether clinical, neuroimaging and pathological features would support such a scheme. In order to accomplish our aims we assessed clinical, neuroimaging and pathological characteristics, including TDP-43 typing, across a large cohort of 195 AD cases that had TDP-43 immunoreactivity.

Materials and methods

Three hundred and forty-two cases with intermediate-high probability AD according to the National Institute on Aging and the Reagan Institute criteria (NIA-Reagan)[40], and Braak neurofibrillary tangle (NFT) stage of IV–VI[6] were utilized in this study. Of these 342 cases, 195 had TDP-43 immunoreactivity while the remainder did not. All cases had been prospectively recruited and followed in the Mayo Clinic Alzheimer's Disease Research Center (ADRC) or Alzheimer Patient Registry (ADPR) between 1992 and 2005. For this study, we assessed education, sex, age at onset, age at death, Mini-Mental State Examination (MMSE)[12], Clinical Dementia Rating Sum of Boxes (CDR-SB)[29], the memory subscore of the Dementia Rating Scale (mDRS)[27], the Boston Naming Test (BNT)[21], and apolipoprotein E (*APOE*) e4 status [8,17].

Briefly, neuropathological examinations had been performed according to the recommendations of the Consortium to Establish a Registry for AD (CERAD)[28] by one of two board certified neuropathologists (DWD or JEP). Each case was assigned a Braak neurofibrillary tangle (NFT) stage [6] using modified Bielschowsky silver stain, on the basis of the earliest appearance of NFT pathology. The presence of Lewy bodies outside of the amygdala was recorded using alpha-synuclein stain. Hippocampal sclerosis (HpScl) was diagnosed on Hematoxylin and Eosin stained slides as the presence of neuronal loss in the subiculum and/or CA1 regions of the hippocampus out of proportion to the burden of NFTs present in these regions [10].

For TDP-43 analysis, formalin-fixed, paraffin-embedded tissue for each region-of-interest were immunostained for TDP-43 (polyclonal antibody MC2085 that recognizes a peptide sequence in the 25-kDa C-terminal fragment [42]) with a DAKO-Autostainer (DAKO-Cytomaton, Carpinteria, California) and 3, 3'-diaminobenzidine as the chromogen. Sections were lightly counterstained with Hematoxylin. For this study, the following regions were reviewed: amygdala, entorhinal cortex, subiculum, dentate gyrus of the hippocampus, OTC, inferior temporal cortex, middle frontal cortex and basal ganglia. For basal ganglia, we assessed the putamen, globus pallidus and caudate. All slides were reviewed simultaneously by two observers (DWD, KAJ) who agreed on the presence of TDP-43 immunoreactivity defined as NCIs, DN or NIIs in any region (TDP-positive). The severity of TDP-43 deposition in the amygdala was graded on a four-point scale (1=scant [one to two inclusions only], 2=sparse, 3=moderate, 4=frequent). TDP-43 typing was performed in cases with hippocampal or neocortical TDP-43 immunoreactive inclusions based on the Harmonized criteria [26].

Two-hundred and forty-eight cases had an antemortem volumetric MRI scan performed according to a standardized protocol, as previously detailed [16]. For this study, the MRI scan closest to death was used. Preprocessing steps included correction for gradient non-linearity and intensity non-uniformity [35]. Grey matter volumes of amygdala, hippocampus, entorhinal cortex, OTC, lateral temporal lobe, and lateral frontal lobe were measured using atlas-based parcellation in SPM5 and the automated anatomic labeling (AAL) atlas [36], as previously described [38]. These regions were selected to mirror the regions included in the pathological analysis. Left and right volumes were averaged for each region. Total intracranial volume was calculated as previously described [39], and used to correct for differences in head size.

Demographic and pathological variables were assessed using chi-square tests for categorical variables and ANOVA for continuous variables. Significance was set at $p < 0.05$. Post-hoc *t*-tests with unequal variances were performed if the ANOVA was significant. Clinical and neuroimaging variables were assessed with ANOVA and logistic regression with age at test and time from disease onset to test included as a covariate. Pair-wise correlations were performed between clinical and neuroimaging continuous variables and the staging scheme. Statistical analyses were performed utilizing JMP (JMP Software, version 9.0.0; SAS Institute Inc., Cary, NC). Results reported as median (inter-quartile range).

Results

TDP-43 in AD staging scheme

Of the 195 TDP-positive cases, three cases were missing some paraffin blocks and were excluded from further analysis. Therefore, staging was performed in 192 cases. Five stages were identified based on the sequential progression of regional TDP-43 deposition in AD (Table 2).

Stage I consisted of 33 cases (17%) which showed scant to sparse involvement of the amygdala (Figure 1). None of these 33 cases showed involvement of the entorhinal cortex, subiculum, dentate gyrus of the hippocampus, OTC, inferior temporal cortex or middle frontal cortex. One case, however, had scant TDP-43 immunoreactive inclusions in the amygdala and basal ganglia (Table 2).

Stage II consisted of 48 cases (25%) which showed involvement of both the amygdala and entorhinal cortex or subiculum (Figure 1). In these cases, TDP-43 deposition in the amygdala was moderate-frequent. Forty-three of the 48 cases had TDP-43 deposition in the entorhinal cortex, of which 29 also had involvement of the subiculum. Five cases in stage II did not show involvement of entorhinal cortex but had TDP-43 immunoreactivity in the amygdala and subiculum (Table 2).

Stage III consisted of 59 cases (31%). The amygdala was involved in all stage III cases, with entorhinal cortex and subiculum involved in all but two cases (Table 2). All stage III cases showed involvement of the dentate gyrus of the hippocampus or the OTC (Figure 1). The majority of these 59 cases (n=51) had involvement of both the dentate gyrus of the hippocampus and the OTC. However, six cases showed involvement of the dentate gyrus of the hippocampus without involvement of the OTC, and two cases showed involvement of the OTC without involvement of the dentate gyrus (Table 2).

Stage IV consisted of 39 cases (20%). The amygdala, entorhinal cortex, subiculum, OTC and inferior temporal cortex were involved in all cases (Figure 1). The dentate gyrus of the hippocampus was involved in all cases but one (Table 2).

Stage V consisted of 13 cases (7%). All but one of the stage V cases showed involvement of amygdala, entorhinal cortex, subiculum, dentate gyrus of the hippocampus, OTC and inferior temporal cortex. All stage V cases showed involvement of the middle frontal cortex or basal ganglia (Figure 1). Of these 13 cases, 11 showed involvement of both the middle frontal cortex and basal ganglia, while two showed involvement of just the middle frontal cortex. One case did not show involvement of the inferior temporal cortex (Table 2).

Clinical, neuroimaging and pathological differences across stages I–V

Demographic variables did not differ across the five stages, although there were trends for differences in age at onset and disease duration (Table 3). All four clinical measures differed across the five stages, with stage I generally showing the best performance and stage V showing the worst performance (Table 3). On post hoc testing, stage I showed better performance on MMSE, CDR-SB and mDRS compared to the other stages, and better performance on BNT than stage III. Stage II showed better performance on CDR-SB, mDRS and BNT compared to stage IV, and better performance on mDRS compared to stage V. In addition, differences were observed between stages III and IV on BNT, and stages III and V on mDRS. Statistically significant correlations were observed between stages I–V and all four clinical measures (Table 4), showing a decline in performance with increasing stage.

Volumes of the hippocampus, entorhinal cortex and lateral frontal lobe differed across the five stages (Table 3). For the hippocampus, stage I showed significantly larger volumes than all the other stages. Stage I also showed the largest entorhinal cortex volume, with significant differences observed from stages III, IV and V. Stage II showed significantly larger entorhinal volumes than stages III and V. Volumes of the lateral frontal lobe were largest in stage I, which differed significantly from stages II, III and V. However, stage IV showed significantly larger volumes than stages II, III and V. Only the hippocampal and entorhinal cortex volumes, but not lateral frontal lobe volume, showed statistically

significant correlations with stage (Table 4), showing that only the hippocampus and entorhinal cortex volumes progressively declined with increasing stage.

The severity of amygdala TDP-43 immunoreactivity increased across the five stages (Table 3), with stages I and II showing lower TDP-43 burdens than stages III, IV and V. The proportion of TDP types A, B and C differed across stages III, IV and V. While the majority of cases in each of these stages showed pathological characteristics consistent with type A, stage III showed the highest proportion of type B cases (36%) and stage V showed the highest proportion of type C cases (15%). The presence of HpScl was rare in stages I and II, but was observed in almost half of the stage III cases and more than three quarters of the stage IV and V cases. No differences were observed across stages in Braak stage or the proportion of Lewy bodies.

TDP-43 in AD stages I-V compared to TDP-negative AD

Clinical and neuroimaging features were also compared between each of the five stages and the 147 AD cases that did not have any TDP-43 immunoreactive inclusions (TDP-negative) (Figure 2). Consistent with the findings above, there was a graded difference in the clinical variables and hippocampal volumes with stage I showing the least differences compared to TDP-negative AD, followed by stage II, stage III and then stage IV. The entorhinal cortex volumes also declined with increasing stage, although the most significant differences from TDP-negative AD were observed at stage III. Clinical performance and hippocampal and entorhinal volumes in stage V were similar to stage IV, although the p values were less striking. The only variable that showed a significant difference between stage I and the TDP-negative AD cases was the BNT. On the contrary, all variables differed between stages II, III, IV and V and the TDP-negative cases, except for the entorhinal cortex in stage II.

Discussion

In our large cohort of patients, we have identified five distinct stages showing stereotypic progression of TDP-43 deposition in AD. TDP-43 deposition in AD occurs first in the amygdala (stage I), and then progresses to entorhinal cortex and subiculum (stage II), followed by hippocampal dentate gyrus and OTC (stage III), and then to temporal (stage IV) and frontal neocortices and basal ganglia (stage V). The staging scheme was validated by significant correlations with clinical and neuroimaging variables and will be important for future clinical, neuroimaging, pathologic and even genetic analyses in AD.

The staging scheme was developed based on the observation of a systematic progressive regional deposition of TDP-43 in AD. All cases in this study had amygdala involvement, with a large proportion having only amygdala involvement suggesting that deposition occurs first in the amygdala and then progresses elsewhere. Using this concept of regional involvement, the entorhinal cortex and subiculum were the next most commonly involved regions. It was difficult, however, to precisely determine whether the entorhinal cortex was affected before the subiculum, or vice versa, given that we had cases with entorhinal involvement without subiculum involvement and cases with subiculum involvement without entorhinal involvement. Although we observed a greater number of cases with involvement of the entorhinal cortex than the subiculum, another study identified more cases with involvement of the subiculum than entorhinal cortex [3]. We observed further progression involving the dentate gyrus of the hippocampus and OTC. These two regions appeared to be simultaneously involved since the great majority of cases showed involvement of both regions. The next region that was apparently involved was the temporal cortex. There were a large number of cases with involvement of the temporal cortex that did not show involvement of the frontal cortex or basal ganglia. Two similar cases have been previously reported [3]. Of cases that spread into the temporal cortices, we observed that in

approximately a third there was additional involvement of the frontal cortex and basal ganglia. In fact, in all but two cases, whenever the frontal cortex was involved the basal ganglia were also involved. This observed pattern of progression from the amygdala through to the frontal cortex and basal ganglia accounted for almost 100% of the cases, with only a few outliers that were missing a preceding region, and one case with amygdala and basal ganglia involvement. The parietal lobe has been assessed in two previous studies, although it is difficult to determine whether parietal involvement follows or precedes frontal involvement [3,15]. Previous studies have suggested that RNA binding proteins, such as TDP-43, have prion-like properties and hence may propagate from cell-to-cell [5,23]. The fact that TDP-43 has been shown to have filamentous properties with electron microscopic analysis [24] and the fact that TDP-43 does progress in a stereotypic fashion in AD support this hypothesis. However, it is unclear why the regional progression in AD would differ from the regional progression of TDP-43 in ALS [7] and why progression in both do not follow an established anatomic route.

The staging scheme extends findings from previous studies that reported different patterns of regional TDP-43 involvement in AD. In the original study by Amador-Ortiz et al. two patterns were described; limbic and diffuse [1]. The former was defined by involvement of the dentate gyrus of the hippocampus and entorhinal cortex, with scant involvement of the OTC. The latter was defined by involvement of OTC and inferior temporal cortex. Therefore, stage III corresponds most closely to the limbic group, while stages IV and V correspond most closely to the diffuse group. This fits with the fact that the limbic group has been previously reported to be more common than the diffuse group [1] and the most common stage was indeed stage III. Subsequent studies identified cases with involvement of only the amygdala, but these studies were limited by a small number of cases and hence were not able to adequately assess progression [3,13,15,22]. Similarly, only two cases with amygdala and entorhinal cortex involvement have been previously reported [3].

We identified clinical, neuroimaging and pathological differences that helped to validate the TDP-43 in AD staging scheme by demonstrating that there were differences between all five stages. Firstly, there were significant clinical and/or neuroimaging differences between stage I and the other four stages, between stages II and III, between stages III and IV, and between stages IV and V. It is unlikely that these findings were driven by age at onset since stage III cases were in fact the oldest, and age was included as a covariate in our analyses. Similarly, for disease duration, the stage II cases had longer disease duration compared to stage III cases, yet did not have worse clinical scores. Second, there were significant differences in the frequency of HpScl, with low frequencies observed in stages I and II, and higher frequencies observed in stages III, IV and V. In fact, stages IV and V showed significantly higher frequencies than all the other stages, with all but one of the stage V cases having HpScl. Hippocampal sclerosis has been previously shown to be associated with TDP-43 deposition [1,9,11,18,22,30,32,37,41], but in this study we further demonstrate that the association is driven by stages III–V. In addition, there was a difference in amygdala TDP-43 burden between stages I and II, with stage I showing scant-sparse inclusions and stage II cases showing moderate-frequent inclusions. This finding further validates the separation of stage I from stage II. We did not observe a difference in the APOE genotype frequencies across stages, suggesting that TDP-43 progression in AD is unrelated to APOE.

In addition to demonstrating differences between all five stages, we also demonstrate differences between all five stages and a large group of AD subjects that were TDP-43 negative. Furthermore, when compared to the AD patients that did not have TDP-43, we identified a graded worsening of cognitive impairment, including memory loss and naming difficulties, as well as volume loss of the hippocampus and entorhinal cortex, across stages.

This decline in clinical and neuroimaging variables also correlated with progression from stage I to V.

It was intriguing that the only variable that showed a significant decline in stage I was the BNT; a test of confrontational naming. While the lack of differences in MMSE, CDR-SB and mDRS can be explained by the absence of entorhinal and hippocampal atrophy in the stage I cases, it is unclear why the BNT showed abnormalities. One possibility may be the sensitivity of the BNT to detect subtle changes in language as compared to the ability of the other cognitive tests to detect subtle changes in other cognitive domains. In fact, in one of our previous studies with a much smaller number of subjects, and hence less power, where we assessed the impact of TDP-43 in AD, only the BNT differed across AD cases with and without TDP-43 [18].

Previously, we and others have applied TDP-43 typing to cases of AD,[3,18,37] with somewhat conflicting results regarding typing. We initially reported in a small sample of 29 cases that the majority of cases were type B,[18] while two other studies reported that the most common type was type A [3,37]. In this current study, of those with hippocampal or neocortical involvement (stages III, IV and V) in which we are able to apply the typing, type A pathology was indeed the most common, with the highest proportion of type A observed in stage IV. Two cases in stage V and one case in stage III had characteristics of FTLTDP type C. Interestingly, one type C case in stage V with a clinical diagnosis of AD had prominent aphasia and anteromedial temporal atrophy on neuroimaging (reminiscent of semantic dementia), as well as pathological burden of TDP-43 similar to the amount observed in FTLTDP (Figure 3). Therefore, whenever AD pathology is identified in cases with prominent aphasia and anteromedial temporal atrophy, TDP-43 pathology should be assessed. We were unable to apply the typing scheme to the stage I and II cases since the typing scheme is based on hippocampal and neocortical TDP-43 deposition. However, typing may be possible by utilizing information from one study that assessed TDP-43 morphology in subcortical regions, including amygdala, across the TDP-43 types in frontotemporal lobar degeneration cases [19].

In conclusion, we have identified five distinct stages of TDP-43 immunoreactivity in AD. Based on these findings, we recommend that pathological screening for TDP-43 deposition in AD begin with assessment of the amygdala. If positive, we then recommend further sequential screening based on the regions that are involved across the stages. Further analysis is now needed to determine the association of additional cortical, subcortical and brainstem regions to these five stages and whether there are biochemical differences between the stages.

Acknowledgments

This study was funded by the US National Institute of Aging (NIA) grants R01-AG037491 (to KAJ), R21-AG038736 (to JLW), P01-AG003949 (to DWD) and P50-AG016574 (to RCP). We wish to thank the families of the patients who donated their brains to science allowing completion of this study. We further wish to thank Kris Johnson, Linda Rousseau, Virginia Phillips and Monica Casey-Castanedes for pathological support.

References

1. Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. *Ann Neurol*. 2007; 61:435–445. [PubMed: 17469117]
2. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem Biophys Res Commun*. 2006; 351:602–611. [PubMed: 17084815]

3. Arai T, Mackenzie IR, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. *Acta neuropathologica*. 2009; 117:125–136. [PubMed: 19139911]
4. Bigio EH, Mishra M, Hatanpaa KJ, et al. TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. *Acta neuropathologica*. 2010; 120:43–54. [PubMed: 20361198]
5. Bigio EH, Wu JY, Deng HX, et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. *Acta neuropathologica*. 2013; 125:463–465. [PubMed: 23378033]
6. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta neuropathologica*. 1991; 82:239–259. [PubMed: 1759558]
7. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann Neurol*. 2013; 74:20–38. [PubMed: 23686809]
8. Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. *J Neurosci Methods*. 1994; 53:125–127. [PubMed: 7823614]
9. Davidson YS, Raby S, Foulds PG, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age hippocampal sclerosis and clinical phenotype. *Acta neuropathologica*. 2011; 122:703–713. [PubMed: 21968532]
10. Dickson DW, Davies P, Bevona C, et al. Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. *Acta neuropathologica*. 1994; 88:212–221. [PubMed: 7810292]
11. Dickson DW, Baker M, Rademakers R. Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. *Neuro-degenerative diseases*. 2010; 7:170–174. [PubMed: 20197700]
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975; 12:189–198. [PubMed: 1202204]
13. Geser F, Robinson JL, Malunda JA, et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. *Arch Neurol*. 2010; 67:1238–1250. [PubMed: 20937952]
14. Higashi S, Iseki E, Yamamoto R, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. *Brain research*. 2007; 1184:284–294. [PubMed: 17963732]
15. Hu WT, Josephs KA, Knopman DS, et al. Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. *Acta neuropathologica*. 2008; 116:215–220. [PubMed: 18592255]
16. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. *Brain : a journal of neurology*. 2008; 131:665–680. [PubMed: 18263627]
17. Josephs KA, Tsuboi Y, Cookson N, Watt H, Dickson DW. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. *Arch Neurol*. 2004; 61:1579–1584. [PubMed: 15477512]
18. Josephs KA, Whitwell JL, Knopman DS, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. *Neurology*. 2008; 70:1850–1857. [PubMed: 18401022]
19. Josephs KA, Stroth A, Dugger B, Dickson DW. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. *Acta neuropathologica*. 2009
20. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. *Neuropathology : official journal of the Japanese Society of Neuropathology*. 2009; 29:566–573. [PubMed: 19422539]
21. Kaplan, E.; Goodglass, H.; Weintraub, S. The Boston Naming Test. Veterans Administration Medical Center, City; 1978.

22. King A, Sweeney F, Bodi I, Troakes C, Maekawa S, Al-Sarraj S. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. *Neuropathology : official journal of the Japanese Society of Neuropathology*. 2010; 30:408–419. [PubMed: 20102526]
23. King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. *Brain research*. 2012; 1462:61–80. [PubMed: 22445064]
24. Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. *Acta neuropathologica*. 2008; 116:205–213. [PubMed: 18607609]
25. Mackenzie IR, Baborie A, Pickering-Brown S, et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. *Acta neuropathologica*. 2006; 112:539–549. [PubMed: 17021754]
26. Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. *Acta neuropathologica*. 2011; 122:111–113. [PubMed: 21644037]
27. Mattis, S. Dementia Rating Scale. Psychological Assessment Resources, City; 1988.
28. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*. 1991; 41:479–486. [PubMed: 2011243]
29. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993; 43:2412–2414. [PubMed: 8232972]
30. Nelson PT, Schmitt FA, Lin Y, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. *Brain : a journal of neurology*. 2011; 134:1506–1518. [PubMed: 21596774]
31. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*. 2006; 314:130–133. [PubMed: 17023659]
32. Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-Radford NR. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. *Alzheimer disease and associated disorders*. 2011; 25:364–368. [PubMed: 21346515]
33. Robinson JL, Geser F, Corrada MM, et al. Neocortical and hippocampal amyloidbeta and tau measures associate with dementia in the oldest-old. *Brain : a journal of neurology*. 2011; 134:3708–3715. [PubMed: 22120149]
34. Sampathu DM, Neumann M, Kwong LK, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. *Am J Pathol*. 2006; 169:1343–1352. [PubMed: 17003490]
35. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. *IEEE transactions on medical imaging*. 1998; 17:87–97. [PubMed: 9617910]
36. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *NeuroImage*. 2002; 15:273–289. [PubMed: 11771995]
37. Uryu K, Nakashima-Yasuda H, Forman MS, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. *Journal of neuropathology and experimental neurology*. 2008; 67:555–564. [PubMed: 18520774]
38. Whitwell JL, Jack CR Jr, Przybelski SA, et al. Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. *Neurobiol Aging*. 2011; 32:1531–1541. [PubMed: 19914744]
39. Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. *Lancet neurology*. 2012; 11:868–877. [PubMed: 22951070]
40. WorkingGroup. Consensus recommendation for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for Neuropathologic Assessment of Alzheimer's Disease. *Neurobiol Aging*. 1997; 18(Supp 1):S1–S2. [PubMed: 9330978]

41. Yokota O, Davidson Y, Bigio EH, et al. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. *Acta neuropathologica*. 2010; 120:55–66. [PubMed: 20512649]
42. Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. *Proc Natl Acad Sci U S A*. 2009; 106:7607–7612. [PubMed: 19383787]

Figure 1. Pathological findings from representative cases for each of the five stages

In stage I, scant-sparse TDP-43 immunoreactive inclusions are observed only in the amygdala. In stage II, inclusions are moderate-frequent in the amygdala and extend into entorhinal cortex, but are not identified in dentate, OTC, temporal or frontal cortices. In stage III, inclusions extend into hippocampus and OTC, but are not identified in temporal or frontal cortices. In stage IV, inclusions extend into the inferior temporal cortex. In stage V, TDP-43 immunoreactivity is widespread and affects the frontal cortex or basal ganglia. Bar = 30 micron. All images are the same magnification. Arrows point to NCI's.

Figure 2. Line plots show significant differences between TDP-negative cases and all five stages
 Data points represent median values for each variable. *p<0.05; **p<0.01; ***p<0.001
 Hippocampal and entorhinal MRI volumes are shown as volume/TIV × 100. MMSE = Mini-Mental State Examination, CDR-SB = Clinical Dementia Rating Sum of Boxes; mDRS = memory subscale of the Dementia Rating Scale; BNT = Boston Naming Test.

Figure 3. Neuroimaging and pathological findings in a case with AD and TDP-43 type C pathology

Top panel shows three coronal T1-weighted MRI slices highlighting left anteromedial temporal lobe atrophy. Bottom panel shows TDP-43 immunoreactive inclusions consistent with FTLD type C, including long thick DN in frontal (a) and insula (b) cortices, and Pick body-like NCIs in the putamen (c) and the hippocampal dentate gyrus (d). Bar = 30 micron

Table 1

Comparison of demographics, clinical and pathological features across studies that have assessed TDP-43 immunoreactivity in >50 AD cases.

Study Origin	Current study	USA- FL	Germany/ USA-PA	Japan/ Canada	USA-IL	UK- Manchester	All studies
Antibody	MC2085	Protein Tech	Protein Tech	pTDP-43	Protein Tech	pTDP-43	Mixed
Total # of cases	342	167	182	78	53	180	1002
Sex ratio M:F	130: 212	77:90	74:108	44:34	27:26	88:92	440: 562
Percent Female	62%	54%	59%	44%	49%	51%	56%
Average age at death, yrs.	87.1	81.7	77.5	79.3	74.4	72.9	80.6 [‡]
Disease duration, yrs.	9.1	NR	8.9	NR	10.6	8.6	9.0
Braak stage, range	IV-VI	IV-VI	V-VI	IV-VI	V-VI	V-VI	IV-VI
Screening region *	Amygdala	Hippo	Hippo	Amygdala	Amygdala	Hippo	Mixed
# TDP positive cases	195 (57%)	61 (36%)	47 (26%)	33 (42%)	17 (32%)	34 (19%)	387 (39%)
Sex ratio M:F	70:125	29:32	16:31	19:14	NR	NR	NA
Percent Female	64%	52%	66%	42%	NA	NA	60%
Age at death, yrs.	88.0	84.5	79.8	82.1	NR	NR	85.6
Disease duration, yrs.	10.0	NR	10.4	NR	NR	NR	10.1

Hippo= hippocampus; NR = Not reported; p-TDP-43 = phosphorylated dependent TDP-43 antibody; FL = Florida; PA = Pennsylvania; IL = Illinois; NA = Not able

[‡] Excluding the USA-IL and UK Manchester series results in an average age of 82.8 (useful in order to compare to age at death for TDP positive cases that we report below)

* Region used to determine whether a subject is considered TDP-positive

Table 2

Patterns of regional TDP-43 immunoreactivity within each stage

	Amgdala	Entorhinal	Subiculum	Dentate	OTC	Inferior temporal	Middle frontal	Basal ganglia	N (%) within stage
STAGE I	+	-	-	-	-	-	-	-	32 (97%)
	+	-	-	-	-	-	-	+	1 (3%)
STAGE II	+	+	+/-	-	-	-	-	-	43 (90%)
	+	-	+	-	-	-	-	-	5 (10%)
STAGE III	+	+	+	+	+/-	-	-	-	55 (93%)
	+	+	+	-	+	-	-	-	2 (3%)
	+	+	-	+	+	-	-	-	1 (2%)
	+	-	+	+	-	-	-	-	1 (2%)
STAGE IV	+	+	+	+	+	+	-	-	38 (97%)
	+	+	+	-	+	+	-	-	1 (3%)
STAGE V	+	+	+	+	+	+	+	+/-	12 (92%)
	+	+	+	+	+	-	+	+	1 (8%)

OTC = Occipitotemporal cortex

Table 3
Demographic, clinical, neuroimaging and pathological features across the five stages

	Stage I	Stage II	Stage III	Stage IV	Stage V	p-values
Demographics						
N	33 (17%)	48 (25%)	59 (31%)	39 (20%)	13 (7%)	
Education, yrs.	15 (12–16)	14 (12–16)	14 (12–16)	13 (12–16)	13 (11–17)	0.60
Percent female	22 (67%)	30 (63%)	38 (64%)	24 (62%)	8 (62%)	0.99
Age onset, yrs.	74 (68–80)	76 (68–82)	82 (73–86)	77 (70–82)	76 (70–80)	0.06
Age death, yrs.	85 (80–89)	87 (82–94)	89 (84–95)	88 (85–93)	85 (82–93)	0.16
DD, yrs.	8 (5–11)	10 (8–14)	9 (6–12)	11 (8–15)	11 (8–13)	0.06
Genetics						
APOE e4 *	26 (79%)	25 (54%)	31 (54%)	24 (65%)	9 (69%)	0.14
23	1 (3%)	1 (2%)	6 (11%)	1 (3%)	0 (0%)	0.34
33	6 (18%)	20 (44%)	20 (35%)	12 (32%)	4 (31%)	
24	2 (6%)	2 (4%)	1 (2%)	2 (5%)	2 (15%)	
34	20 (61%)	18 (39%)	24 (42%)	15 (41%)	5 (39%)	
44	4 (12%)	5 (11%)	6 (11%)	7 (19%)	2 (15%)	
Clinical						
MMSE (/30)	20 (12–25)	14 (9–20)	15 (9–19)	12 (8–16)	13 (7–19)	0.02 ^{a,b,c,d}
CDR-SB (/18)	7 (3–14)	14 (5–18)	13 (7–18)	17 (10–18)	17 (12–18)	0.001 ^{a,b,c,d,f}
mDRS (/25)	12 (8–17)	10 (7–14)	10 (7–14)	9 (6–11)	7 (5–10)	0.002 ^{b,c,d,f,g,i}
BNT (/60)	35 (20–47)	37 (24–45)	31 (26–41)	27 (16–36)	28 (21–36)	0.05 ^{c,f,h}
Neuroimaging						
Amygdala	0.12 (0.11–0.13)	0.12 (0.11–0.13)	0.12 (0.10–0.13)	0.12 (0.11–0.13)	0.12 (0.11–0.12)	0.29
Hippocampus	0.43 (0.38–0.47)	0.38 (0.34–0.44)	0.38 (0.33–0.43)	0.38 (0.32–0.42)	0.36 (0.27–0.42)	0.008 ^{a,b,c,d}
Entorhinal	0.17 (0.16–0.19)	0.16 (0.14–0.18)	0.15 (0.13–0.18)	0.16 (0.13–0.18)	0.16 (0.12–0.17)	0.01 ^{b,c,d,e,g}
OTC	1.10 (1.01–1.19)	1.08 (0.96–1.21)	1.05 (1.00–1.12)	1.07 (1.00–1.13)	1.03 (0.85–1.10)	0.30
Lat. temporal	4.22 (3.89–4.69)	3.99 (3.61–4.19)	4.04 (3.64–4.37)	4.04 (3.71–4.42)	3.76 (3.36–4.57)	0.29
Lat. frontal	3.91 (3.46–4.15)	3.43 (3.23–3.92)	3.70 (3.10–3.90)	3.78 (3.52–4.16)	3.29 (2.80–4.29)	0.03 ^{a,b,d,f,h,j}

	Stage I	Stage II	Stage III	Stage IV	Stage V	p-values
Pathological						
Amygdala TDP severity	2 (2-2)	3 (2-3)	4 (3-4)	4 (4-4)	4 (3-4)	< 0.0001 ^{a,b,c,d,e,f,g}
TDP type						
A	NA	NA	37 (63%)	38 (97%)	11 (85%)	<0.0001 ^{b,i,j}
B	NA	NA	21 (36%)	1 (3%)	0 (0%)	
C	NA	NA	1 (2%)	0 (0%)	2 (15%)	
Braak stage						
IV	7 (21%)	7 (15%)	9 (15%)	7 (18%)	3 (23%)	0.39
V	7 (21%)	17 (35%)	22 (37%)	6 (15%)	3 (23%)	
VI	19 (58%)	24 (50%)	28 (48%)	26 (67%)	7 (54%)	
Lewy bodies	8 (24%)	19 (40%)	20 (34%)	15 (38%)	3 (23%)	0.49
HpScl	4 (12%)	3 (6%)	26 (45%)	32 (82%)	12 (77%)	
						<0.0001 ^{b,c,d,e,f,g,h,i}

Data shown as median (inter-quartile range). MMSE = Mini-Mental State Examination; CDR-SB = Clinical Dementia Rating Sum of Boxes; mDRS = Dementia Rating Scale memory subscore; BNT = Boston Namin g Test; APOE= apolipoprotein E; DD = disease duration; OTC = occipitotemporal cortex; Lat = lateral; NA = Not applicable

*Two cases in each of stage II, III and IV were missing APOE genotyping

Post-hoc p values were considered significant if <0.05:

a= Stage I vs. II	b= Stage I vs. III
c= Stage I vs. IV	d= Stage I vs. V
e= Stage II vs. III	f= Stage II vs. IV
g= Stage II vs. V	h= Stage III vs. IV
i= Stage III vs. V	j= Stage IV vs. V

Table 4

Correlations between clinical and neuroimaging features with the five stages

	r	p value
MMSE	−0.23	0.002
CDR-SB	0.30	<0.0001
mDRS	−0.30	<0.0001
BNT	−0.20	0.01
Hippocampal volume	−0.27	0.01
Entorhinal cortex volume	−0.26	0.002
Lateral frontal volume	−0.05	0.54

MMSE = Mini-mental State Examination; CDR-SB = Clinical Dementia Rating Scale Sum of Boxes; mDRS = Dementia Rating Scale memory subscore; BNT = Boston Naming Test